E Fund Management Co. Ltd. Has $888,000 Stake in Insmed Incorporated (NASDAQ:INSM)

E Fund Management Co. Ltd. decreased its position in Insmed Incorporated (NASDAQ:INSM) by 11.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 12,858 shares of the biopharmaceutical company’s stock after selling 1,693 shares during the period. E Fund Management Co. Ltd.’s holdings in Insmed were worth $888,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Insmed by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after purchasing an additional 172,664 shares during the period. Principal Financial Group Inc. raised its stake in shares of Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares during the period. Vestal Point Capital LP raised its stake in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Insmed by 7.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company’s stock valued at $106,778,000 after purchasing an additional 102,341 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company’s stock valued at $70,260,000 after purchasing an additional 24,025 shares during the period.

Insmed Trading Down 0.2 %

Insmed stock opened at $74.89 on Friday. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $13.56 billion, a P/E ratio of -13.40 and a beta of 1.28. The stock has a 50-day simple moving average of $75.66 and a 200 day simple moving average of $73.83.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the completion of the sale, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. The trade was a 4.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 1,066 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 550,957 shares of company stock worth $42,859,028 over the last quarter. Company insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Wells Fargo & Company raised their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Morgan Stanley raised their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Royal Bank of Canada assumed coverage on Insmed in a report on Tuesday, February 25th. They issued an “outperform” rating and a $100.00 price objective for the company. Finally, Stifel Nicolaus decreased their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.